Shares of Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the eight brokerages that are presently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $48.33.
Several equities analysts have weighed in on PTHS shares. Alliance Global Partners cut Pelthos Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 13th. Lake Street Capital decreased their price objective on Pelthos Therapeutics from $50.00 to $40.00 and set a “buy” rating on the stock in a report on Monday, October 12th. Piper Sandler reiterated an “overweight” rating and set a $21.00 target price (down from $48.00) on shares of Pelthos Therapeutics in a research report on Friday, November 13th. Oppenheimer cut their target price on shares of Pelthos Therapeutics from $66.00 to $64.00 and set an “outperform” rating for the company in a report on Friday, August 14th. Finally, Zacks Research upgraded shares of Pelthos Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, November 4th.
View Our Latest Stock Analysis on Pelthos Therapeutics
Hedge Funds Weigh In On Pelthos Therapeutics
An institutional investor recently raised its position in Pelthos Therapeutics stock. Pale Fire Capital SE lifted its holdings in Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS – Free Report) by 59.5% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 12,919 shares of the company’s stock after buying an additional 4,819 shares during the period. Pale Fire Capital SE owned about 0.38% of Pelthos Therapeutics worth $271,000 at the end of the most recent reporting period. 77.96% of the stock is currently owned by institutional investors.
Pelthos Therapeutics Stock Performance
PTHS opened at $7.10 on Thursday. The firm has a 50-day simple moving average of $17.14 and a two-hundred day simple moving average of $23.18. Pelthos Therapeutics has a 52 week low of $6.02 and a 52 week high of $31.65. The company has a debt-to-equity ratio of 3.40, a current ratio of 1.78 and a quick ratio of 1.10.
Pelthos Therapeutics (NYSEAMERICAN:PTHS – Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported ($2.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.83) by $0.79. The firm had revenue of $15.39 million for the quarter. Pelthos Therapeutics had a negative return on equity of 432.23% and a negative net margin of 123.24%. Equities analysts predict that Pelthos Therapeutics will post -14.49 EPS for the current year.
Pelthos Therapeutics Company Profile
Pelthos Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for dermatologic conditions. Its portfolio includes ZELSUVMI (berdazimer) topical gel, an FDA-approved prescription treatment for molluscum contagiosum, a viral skin infection. ZELSUVMI is approved in the United States for adults and children aged one year and older. The topical treatment is designed for application at home, providing an option for patients and caregivers managing the condition.
Further Reading
- Five stocks we like better than Pelthos Therapeutics
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Pelthos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pelthos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
